Australia Markets closed

Cannabis company Althea surges higher on German expansion plans

James Mickleboro

In morning trade the Althea Group Holdings Ltd (ASX: AGH) share price has surged higher following an announcement.

At the time of writing the cannabis company’s shares are up 8% to 47 cents.

Why is the Althea share price charging higher?

Investors have been buying Althea’s shares this morning after it announced plans to expand into the Germany market.

According to the release, Althea has signed a memorandum of understanding (MOU) with nimbus health for the sale and distribution of Althea’s medicinal cannabis products in Germany through its pharmacy network.

Nimbus is a leading wholesale pharmaceutical licence holder based in Frankfurt, Germany. It specialises in the distribution and import of medicinal cannabis products and estimates that it has access to 25% of all German medicinal cannabis patients through its pharmacy network.

Althea anticipates the first shipment of its medicinal cannabis products arriving in Germany early in the first half of 2020. Relevant applications for import and export permits will be lodged now that the MOU has been executed.

What now?

In order to support its entry into the Germany market, Althea is following the same strategy that has been successfully implemented in Australia and the UK.

It will develop a localised version of its Althea Concierge platform and its Medicinal Education in Cannabinoids learning portal in Germany.

Thanks to these initiatives and Nimbus’ strong market position, management believes it will be ideally positioned to compete in the German market and quickly build market share.

Which could potentially be very lucrative. The release advises that Prohibition Partners estimates that the German medical cannabis market will be worth €7.7 billion by 2028.

Althea CEO Josh Fegan said: “We are very pleased to have entered into this MOU with Nimbus. Working within an existing and successful distribution channel in Germany is a low risk and high reward strategy for us. The regulatory and social acceptance of medicinal cannabis use in Germany is favourable and we are expecting immediate patient growth in what is one of Europe’s largest and most affluent countries.”

Whilst this has the potential to be a big positive, I feel it is a little soon to get excited. Firstly, MOUs are not legally binding and, secondly, there is nothing to say that any deal will be exclusive.

The post Cannabis company Althea surges higher on German expansion plans appeared first on Motley Fool Australia.

Instead of putting your money in high risk pot stocks, I would invest it in one of these quality growth shares.

NEW. Five Cheap and Good Stocks to Buy in 2020….

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.


More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019